TOKYO -- Beverage group Kirin Holdings is shifting focus to health and pharmaceuticals, allocating more of its medium-term growth investment for these segments than for beer and soft drinks for the first time.
Pharmaceuticals
Kirin leans into health products and drugs, pouring in $900m
Majority of growth investment set aside for these segments for 1st time
Kirin's iMUSE series of health drinks contain lactic acid bacteria said to have immunity benefits.
Read Next
Latest on Pharmaceuticals
